(Q45071385)

9 December 2017

title

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease (English)

1 reference

9 December 2017

0 references

Yahya Karaman

1

1 reference

9 December 2017

Füsun Erdoğan

2

1 reference

9 December 2017

Emel Köseoğlu

3

1 reference

9 December 2017

Tayfun Turan

4

1 reference

9 December 2017

Ali Ozdemir Ersoy

5

1 reference

9 December 2017

publication date

21 September 2004

1 reference

Dementia and Geriatric Cognitive Disorders

9 December 2017

published in

1 reference

9 December 2017

volume

19

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

51-56

1 reference

Tuberculous meningitis in the southwest United States: a community-based study

9 December 2017

cites work

1 reference

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease

21 January 2018

1 reference

An update on primary drug therapies for Alzheimer disease

21 January 2018

1 reference

Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial

21 January 2018

1 reference

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

21 January 2018

1 reference

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

21 January 2018

1 reference

Use of anticholinergic medications by older adults with dementia

21 January 2018

1 reference

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

21 January 2018

1 reference

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

21 January 2018

1 reference

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

A review of rivastigmine: a reversible cholinesterase inhibitor

21 January 2018

1 reference

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease

21 January 2018

1 reference

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

21 January 2018

1 reference

Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease

21 January 2018

1 reference

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000080972

1 reference

9 December 2017

1 reference